When investing in the health care sector, investors often need to weigh the stability of established pharmaceutical giants against the explosive growth potential of emerging biotechnology companies. Amgen (AMGN) and Iovance Biotherapeutics (IOVA) are quintessential representatives of this investment dilemma—the former boasting a vast drug portfolio and deep industry roots, while the latter is a niche player focused on cutting-edge tumor-infiltrating lymphocyte therapies. Although both companies operate within the health care field, their financial profiles and developmental stages offer distinctly different investment theses for investors looking toward 2026.
Amgen is dedicated to discovering and producing drugs for the treatment of serious illnesses, with operations spanning more than 50 countries worldwide, including major markets such as Europe and Japan. The company relies heavily on three major pharmaceutical wholesalers—McKesson Corporation, Cencora, and Cardinal Health—which together accounted for 77% of its global total revenue in 2025. This concentration of customer base introduces certain risks to the business.
In fiscal year 2025, Amgen generated nearly $36.7 billion in revenue, representing year-over-year growth of approximately 9.9%. This revenue performance supported net income of close to $7.7 billion, with a net profit margin of roughly 21.0%, reflecting healthy profitability on the back of its substantial sales scale. As of its December 2025 balance sheet, the company’s debt-to-equity ratio stood at about 6.3 times, indicating that the company employs significant financial leverage to support operations. The current ratio was approximately 1.1 times, demonstrating the ability to cover short-term obligations. Free cash flow for the full year approached $8.1 billion.
Iovance Biotherapeutics is one of the emerging biotechnology companies, focusing on tumor-infiltrating lymphocyte therapies. Its main products, Amtagvi and Proleukin, are distributed through a network of authorized treatment centers and pharmaceutical distributors. The company relies on its own internal manufacturing facility, iCTC, to control its complex production process, and its success depends on the clinical adoption of these innovative therapies in the oncology treatment landscape.
In fiscal year 2025, Iovance generated approximately $263.5 million in revenue, representing year-over-year growth of 60.6%. Despite rapid growth, the company still recorded a net loss of about $391 million, with a net profit margin of negative 148.4%, indicating that the company remains in a phase of heavy investment to support clinical development and commercial launches—a common state for young biotech companies before achieving large-scale commercial success. As of December 2025, its debt-to-equity ratio was approximately 0.1 times, indicating an extremely low level of liabilities. The current ratio stood at about 3.2 times, showing strong short-term solvency. Free cash flow for the full year was negative approximately $336.2 million, meaning the company is consuming cash reserves to fund operations.
From a valuation perspective, Amgen presents a more traditional value-investment profile, with established earnings multiples, while Iovance’s valuation reflects its early-stage growth characteristics. Amgen’s forward price-to-earnings ratio is 15.1 times, below the industry benchmark (SPDR XLV sector ETF) of 24.6 times. In terms of price-to-sales ratios, Amgen stands at 5.0 times, while Iovance is at 5.4 times.
In summary, Amgen, with its robust revenue scale, sustained profitability, and reliable dividend policy, presents a more attractive investment value at the current juncture. For investors with a higher risk tolerance, Iovance is worth watching, but for long-term holding purposes, Amgen’s stable characteristics are more appealing in the current environment.
